Amphastar Pharmaceuticals, Inc. AMPH
26.13
(0.14)
(0.53%)
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 15.0×
Follow AMPH
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
11.29 | 12.75 | 11.46 | 11.60 |
P/S ratio |
1.71 | 1.74 | 1.23 | 1.21 | |
P/FCF ratio |
11.17 | 10.53 | 6.69 | 5.85 | |
P/Operating CF |
23.55 | 38.09 | 18.56 | 17.16 | |
P/B ratio |
1.59 | 1.59 | 1.15 | 1.15 | |
Price to Tangible BV |
6.06 | 5.62 | 4.15 | 7.32 | |
EV/Sales |
2.17 | 2.19 | 1.67 | 1.64 | |
EV/EBITDA |
7.51 | 7.87 | 6.79 | 6.87 | |
EV/Operating CF |
10.31 | 10.10 | 7.14 | 6.50 | |
EV/FCF |
14.16 | 13.27 | 9.07 | 7.98 | |
Quick Ratio |
2.08 | 2.82 | 2.75 | 1.67 | |
Current Ratio |
3.12 | 4.02 | 3.85 | 2.40 | |
Net Debt/EBITDA |
8.20 | 6.40 | 11.03 | 5.82 | |
Debt/Assets |
36.58% | 37.46% | 37.10% | 35.10% | |
Debt/Equity |
0.78 | 0.77 | 0.79 | 0.80 | |
Asset Turnover |
0.45 | 0.45 | 0.44 | 0.43 | |
Operating CF/Net income |
3.03 | 1.35 | 7.45 | 1.69 | |
Capex/Depreciation |
(0.36) | (0.54) | (0.63) | (0.57) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
11.65% | 12.73% | 15.62% | 12.05% | |
Selling, General and Administrative Expense of Revenue |
26.57% | 14.61% | 17.50% | 17.17% | |
Intangible Assets out of Total Assets |
0.34 | 0.35 | 0.34 | 0.37 | |
Share Based Compensation of Revenue |
3.28% | 3.39% | 5.42% | 3.86% | |
Graham Net Nets |
(0.20) | (0.16) | (0.27) | (0.39) | |
Graham Number |
29.79 | 28.24 | 25.62 | 26.25 | |
Earnings Yield |
8.86% | 7.84% | 8.73% | 8.62% | |
Free Cash Flow Yield |
8.95% | 9.49% | 14.96% | 17.09% | |
Revenue per Share |
4.13 | 3.92 | 3.78 | 4.21 | |
Operating CF per Share |
1.13 | 0.70 | 1.06 | 1.18 | |
Capex per Share |
(0.12) | (0.18) | (0.21) | (0.20) | |
Free Cash Flow per Share |
1.02 | 0.53 | 0.85 | 0.98 | |
Cash per Share |
6.00 | 6.10 | 6.50 | 6.70 | |
Shareholders Equity per Share |
16.71 | 16.88 | 17.06 | 17.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.71 | 16.88 | 17.06 | 17.60 | |
Free Cash Flow |
47.24 | 24.59 | 38.33 | 42.73 | |
Working Capital |
434.24 | 477.86 | 469.21 | 367.75 | |
Capital Expenditures |
(5.35) | (8.27) | (9.51) | (8.59) | |
Net Current Asset Value |
(250.01) | (204.48) | (241.09) | (344.66) | |
EV/EBIT |
10.47 | 11.23 | 10.32 | 10.50 | |
Capex to Sales |
0.03 | 0.05 | 0.06 | 0.05 | |
Net Profit Margin |
9.04% | 13.34% | 3.75% | 16.50% | |
Price to Operating Income |
8.26 | 8.92 | 7.61 | 7.71 | |
| Other line items | |||||
Average Receivables |
146.93 | 149.38 | 151.42 | 141.04 | |
Average Payables |
172.06 | 152.70 | 164.31 | 208.96 | |
Average Inventory |
158.12 | 165.32 | 177.84 | 185.82 | |
Average Assets |
1,605.70 | 1,603.38 | 1,637.22 | 1,679.55 | |
Average Common Equity |
752.21 | 760.55 | 762.34 | 762.82 |
Columns are period end dates